Memorial Sloan Kettering doctors are constantly working to improve treatment for people with melanoma through clinical trials. Participating in a clinical trial may give you access to promising melanoma treatments years before they’re available elsewhere. These studies may offer additional options if the cancer has returned after standard treatment.
Through research conducted at MSK, we’ve made enormous strides in improving the treatment options available to people worldwide. Our melanoma clinical trials have resulted in dramatic improvements in survival and quality of life for people with melanoma. Many of the effective melanoma treatments developed over the past decade were studied and tested by members of our melanoma clinical trials team. This includes the immunotherapy drugs ipilimumab (Yervoy®), nivolumab (Opdivo®), and pembrolizumab (Keytruda®), as well as the targeted therapy vemurafenib (Zelboraf®).
Our experts can help determine which clinical trial is right for you, including some of our newly opened clinical trials:
- 20-471 A Phase II/III Study of Immunotherapy with Nivolumab, Ipilimumab, and GM-CSF in Patients with Advanced Melanoma
- 21-286 A Phase II Study of CMP-001 and Nivolumab in People with Advanced Melanoma that Persists Despite Immunotherapy
- 21-295 A Phase I Study of FHD-286 in People with Uveal Melanoma
- 21-456 CD8+ T Cell Imaging During Immunotherapy Before Surgery in People with Melanoma
- 21-466 A Phase II Study of Selinexor Plus Pembrolizumab Immunotherapy to Treat Advanced Melanoma
A complete listing of clinical trials that are currently enrolling new patients is available below.